Glass House Brands (GLAS) Retained Earnings (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Retained Earnings of -$237.2 million for Q1 2026, down 18.32% year-over-year from -$290.4 million in Q1 2025, and down 7.78% quarter-over-quarter from -$220.1 million in Q4 2025.
Glass House Brands (GLAS) Retained Earnings (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Retained Earnings for 7 consecutive years, with -$237.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 18.32% year-over-year to -$237.2 million; the TTM figure through Mar 2026 stood at -$237.2 million (down 18.32% YoY), while the FY2025 annual figure was -$220.1 million, down 15.58% from the prior year.
- Retained Earnings declined to -$237.2 million in Q1 2026 per GLAS's latest filing, from -$220.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$79.6 million in Q3 2022 and bottomed at -$237.2 million in Q1 2026.
- Historically, Retained Earnings has averaged -$167.6 million across 5 years, with a median of -$190.9 million in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 1243.84% — and 2025, when it grew 4.2%.
- Glass House Brands' Retained Earnings stood at -$92.7 million in 2022, then slumped by 106.05% to -$190.9 million in 2023, then advanced by 0.27% to -$190.4 million in 2024, then fell by 15.58% to -$220.1 million in 2025, then slipped by 7.78% to -$237.2 million in 2026.
- Business Quant data shows GLAS's Retained Earnings at -$237.2 million in Q1 2026, -$220.1 million in Q4 2025, and -$204.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 3.75 Bn |
| 10 | Glass House Brands | 825.81 Mn | 807.26 Mn | 15.77 Mn | -244.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -237.21 Mn |
| Dec 31, 2025 | -220.08 Mn |
| Sep 30, 2025 | -204.10 Mn |
| Jun 30, 2025 | -191.81 Mn |
| Mar 31, 2025 | -200.48 Mn |
| Dec 31, 2024 | -190.42 Mn |
| Sep 30, 2024 | -202.52 Mn |
| Jun 30, 2024 | -199.27 Mn |
| Mar 31, 2024 | -209.27 Mn |
| Dec 31, 2023 | -190.94 Mn |
| Sep 30, 2023 | -160.37 Mn |
| Jun 30, 2023 | -160.10 Mn |
| Mar 31, 2023 | -135.09 Mn |
| Dec 31, 2022 | -92.67 Mn |
| Sep 30, 2022 | -79.62 Mn |
| Jun 30, 2022 | -94.80 Mn |
| Mar 31, 2022 | -80.63 Mn |
| Dec 31, 2021 | -59.76 Mn |
| Sep 30, 2021 | -42.26 Mn |
| Mar 31, 2021 | -6.00 Mn |